Assay Report
Methods · Standard Curves · QC · Results
Simultaneous ultra-sensitive digital quantification of core neurodegenerative and acute brain injury biomarkers — including Neurofilament Light (NfL), Glial Fibrillary Acidic Protein (GFAP), Ubiquitin C-Terminal Hydrolase L1 (UCH-L1), Total Tau (t-Tau), BD-Tau, and Amyloid-Beta peptides (Aβ42/Aβ40) — from a single micro-volume sample aliquot.
Deconvoluting the complex interplay between neuroaxonal degradation, reactive astrogliosis, acute somatodendritic necrosis, and amyloid proteopathy requires synchronized multi-analyte tracking. Creative Proteomics delivers fit-for-purpose study designs and high-precision research datasets across preclinical neuroscience pipelines.
Aligning multi-marker half-lives, collection kinetics, and plate randomization for neurotrauma and neurodegeneration cohorts.
Because different biomarkers exhibit vastly different clearance rates (e.g., UCH-L1 clears in hours, whereas NfL persists for weeks), structuring an effective preclinical multiplex study requires precise kinetic timing. Creative Proteomics establishes five universal design dimensions prior to testing:
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Kinetic Sampling Windows | Hyper-acute phase (0–24 h: UCH-L1, GFAP) vs. subacute/chronic phase (Day 3–30+: NfL, Tau) | Captures acute somatodendritic cytolysis before UCH-L1 drops while monitoring long-term axonal rescue via NfL. |
| Panel Configuration & Kinetic Timing | Selecting N4PA/N4PB (Trauma/Axonal), N4PD (Brain-Derived Specificity), or N4PE (Amyloid ATN) | Matches the multiplex bead configuration directly to your disease model or therapeutic mechanism of action. |
| Baseline & Vehicle Controls | Pre-dose / pre-injury intra-individual baselines vs. age-matched parallel non-transgenic cohorts | Separates genuine therapeutic neuroprotection from age-related neurodegenerative accumulation. |
| Micro-Volume Efficiency | 15 μL net volume yielding 4 simultaneous data points + duplicate confirmation reserve | Conserves precious longitudinal small-animal biofluids (e.g., serial submandibular bleeds) over extended regimens. |
| Plate Balancing & Randomization | Balancing vehicle, candidate drug doses, and longitudinal timepoints across analytical disc runs | Eliminates confounding between true experimental treatment effects and run-to-run assay variance. |
Tailored 4-plex and custom multiplex panel configurations optimized for specific neurodegenerative and neurotrauma indications.
| Panel Configuration | Simultaneous Analytes | Target Disease Area | Key Preclinical Strength |
|---|---|---|---|
| Neurology 4-Plex A (N4PA) / B (N4PB) | NfL, GFAP, UCH-L1, Total Tau | TBI, Concussion, Stroke, Spinal Cord Injury, Amyotrophic Lateral Sclerosis (ALS) | Complete deconvolution of acute cytolysis (UCH-L1), astrogliosis (GFAP), and structural axonal loss (NfL/Tau). |
| Neurology 4-Plex D (N4PD) | BD-Tau, NfL, GFAP, UCH-L1 | Alzheimer's, Mixed Dementia, Cortical Injury | Integrates brain-derived tau (BD-Tau) to eliminate non-CNS peripheral tau interference during multi-marker profiling. |
| Neurology 4-Plex E (N4PE) | Aβ40, Aβ42, GFAP, NfL | Alzheimer's Disease, Amyloid Plaque Dynamics | Simultaneously evaluates amyloid cascade progression (Aβ42/40 ratio) alongside astroglial inflammation and axonal damage. |
| Neurology 2-Plex / 3-Plex Options | NfL + GFAP or Aβ40 + Aβ42 + Tau | Targeted Efficacy Screening & Safety Profiling | Streamlined multi-marker configurations for focused lead candidate optimization and high-throughput drug screening. |
Evaluating multiplex sensitivity, sample conservation, and data continuity across bioanalytical platforms for preclinical neuroscience programs.
| Technical Dimension | Conventional Plate ELISA | Luminex xMAP Multiplex | MSD ECL Platform | Quanterix Simoa HD-X Multiplex (Our Service) |
|---|---|---|---|---|
| Sample Volume for 4 Analytes | 200 – 400 μL (50–100 μL × 4) | 25 – 50 μL total | 25 – 50 μL total | 15 μL total net volume |
| Analytical LLOQ Range | 15.0 – 50.0 pg/mL | 1.0 – 10.0 pg/mL | 1.0 – 5.0 pg/mL | 0.05 – 1.8 pg/mL (Sub-pg/mL) |
| Basal Blood Detectability | <30% (High dropout rate) | 50% – 70% (Baseline dropout risk) | 70% – 85% (CSF optimal; plasma variable) | 100% Quantifiable for NfL, GFAP, Tau |
| Multiplex Capacity | Singleplex (1 target/well) | High Multiplex (Up to 50–100 plex) | Medium Multiplex (1–10 plex) | Focused Low-Plex (1–4 plex) |
| Optical / Spectral Crosstalk | N/A (Individual wells) | Low (Fluorescent bead deconvolution) | Low (Spatial spot separation) | Zero (Digitally isolated femtoliter wells) |
| Linear Dynamic Range | 2.0 – 2.5 logs | 3.0 – 3.5 logs | 4.0 – 5.0 logs | >4.5 logs (Poisson digital + Analog) |
| Serial Small Rodent Profiling | Impossible without sacrifice | Moderate | Moderate | Standard protocol for serial live draws |
| Primary Matrix Fit | In vitro cell models | Large multi-species discovery | CSF, tissue lysates, high-abundance | Peripheral blood (serum/plasma), micro-fluids |
Comparing data generated on singleplex assays or legacy multi-spot platforms (such as MSD or Luminex) with Simoa multiplex panels requires structured bioanalytical method bridging. Because antibody avidity, dye conjugation ratios, and bead surface chemistry differ slightly between singleplex and multiplex formats, a consistent proportional offset (typically 5–15%) is often observed despite near-perfect correlation (r > 0.96).
Our Bridging Protocol: We test a representative bridging cohort (15–20 paired baseline and elevated specimens) across both assay formats to establish a validated mathematical conversion equation, ensuring seamless data continuity across multi-year studies.
Multi-analyte specifications validated under strict FDA Bioanalytical Method Validation (BMV) and International Council for Harmonisation (ICH) M10 criteria.
Validation of zero signal bleed-through across 4 distinct dye-encoded bead populations loaded into physically isolated 50 fL microwells on optical discs.
Analytical calibration balancing short-lived acute lysis markers (UCH-L1 <24h) with long-lived structural breakdown markers (NfL ~3 weeks).
Multi-point QC verification ensuring all 4 targets (NfL, GFAP, UCH-L1, Tau/BD-Tau) simultaneously achieve intra-assay CV <8% and inter-assay CV <12%.
Specimens received on dry ice are barcode-logged, assessed for hemolysis/lipemia, and cataloged into monitored −80 °C storage.
Automated liquid handling performs 1:4 sample dilution in matrix-matched assay diluent supplemented with heterophilic blocking agents.
A mixture of 4 dye-encoded magnetic bead populations captures NfL, GFAP, UCH-L1, and Tau simultaneously, followed by blended detector binding.
Bead-enzyme complexes (SBG) are loaded onto optical Simoa discs with 216,000 femtoliter wells, sealed with oil, and imaged for dual-color fluorescence.
Software deconvolutes bead barcodes and calculates absolute pg/mL concentrations, replicate statistics, and multi-analyte correlation ratios.
A standardized pre-analytical framework to harmonize specimen stability across divergent multiplex biomarker half-lives.
| Pre-Analytical Parameter | Why It Matters for Multi-Analyte Bioanalysis | Intake Specification & Recommendation |
|---|---|---|
| Anticoagulant Selection | NfL, GFAP, and Tau perform robustly in K2-EDTA; heparin tubes cause polyanionic interference and suppress signals by 10–15 %. | K2-EDTA plasma is strongly preferred; serum is acceptable if clotted consistently for 30–60 min at RT. |
| Centrifugation Timing | UCH-L1 degrades rapidly in unseparated blood due to endogenous proteases; GFAP requires rapid separation to avoid platelet activation background. | Centrifuge at 2,000 μg for 15 min at 4 °C within 60 minutes of collection; harvest platelet-poor plasma. |
| Protease & Phosphatase Control | Tissue homogenates contain active proteases and phosphatases that rapidly degrade peptide epitopes post-lysis. | Supplement lysis buffers with broad-spectrum protease (PMSF, EDTA) and phosphatase inhibitors (1 mM Na3VO4, 50 mM NaF). |
| Freeze-Thaw Management | While NfL and GFAP withstand 4–5 freeze-thaw cycles, UCH-L1 and Aβ peptides are highly sensitive to repeated freezing. | Aliquot immediately into polypropylene cryovials; store at −80 °C; ship strictly on dry ice (minimum 5–8 kg). |
| Sample Net Volume | A single 15 μL sample draw yields 4 distinct quantitative biomarker readouts, conserving small-animal cohorts. | 15 μL net volume per well (30 μL recommended to support duplicate verification and analytical reserve). |
| Run Allocation & Balancing | Placing baseline and post-treatment cohorts on separate plates risks confounding treatment effects with batch variance. | We pre-plan plate layouts so that paired longitudinal timepoints and cohort groups are balanced across the same run. |
Empowering multi-target drug discovery, acute trauma staging, and preclinical pipeline de-risking.
Simultaneously track acute somatic necrosis (UCH-L1), rapid astrogliosis (GFAP), and progressive axonal injury (NfL) post-ischemia.
Disentangle acute blood-brain barrier disruption and astrocytic reactivity from cumulative long-term axonal shear strain.
Evaluate poly-pharmacological drug candidates against multiple cellular injury pathways from a single 15 μL sample aliquot.
Longitudinal profiling of astrogliosis versus axonal loss across aging transgenic mouse models of AD, ALS, and PD.
Measure suppression of reactive astrocytosis (GFAP) alongside structural axonal preservation (NfL) post-treatment.
Generate 4 publication-grade biomarker readouts from a single 15 μL sample aliquot, preserving precious longitudinal rodent cohorts.
quality-controlled bioanalytical documentation and PhD-level consultation for every testing project.
Landmark peer-reviewed studies establishing multiplex single-molecule biomarker profiling across CNS disorders.
Study Design Takeaway: Demonstrates that UCH-L1 and GFAP peak acutely (<24h) following injury, whereas NfL exhibits sustained elevation for weeks, validating complementary kinetic sampling.
Study Design Takeaway: Proves that pairing GFAP (astrogliosis) with NfL (axonal loss) provides superior predictive accuracy for disease progression than either marker alone.
Study Design Takeaway: Details the distinct subcellular compartmentalization of tau and neurofilaments, reinforcing the need for multi-marker profiling.
Study Design Takeaway: Establishes the technical foundation for zero optical crosstalk and single-molecule accuracy in bead-encoded 4-plex immunoassays.
Study Design Takeaway: Demonstrates high translational biomarker performance when combining Aβ42/40 with GFAP and NfL across longitudinal cohorts.
Addressing common bioanalytical and project planning inquiries.
Multiplexing on the Quanterix Simoa HD-X analyzer utilizes distinct populations of paramagnetic beads, each encoded with a unique ratio of fluorescent dyes (dye codes). Each bead population is conjugated to a specific monoclonal capture antibody. When loaded into the 216,000 femtoliter disc microwells, automated optical imaging identifies the bead type by its fluorescent signature and detects target binding via the single-molecule SBG enzyme signal, ensuring zero analytical cross-reactivity.
Yes. NfL and GFAP exhibit high evolutionary homology and cross-react robustly across rodent species. However, certain human-specific Total Tau or UCH-L1 antibody clones may have lower cross-reactivity in wild-type rodents. In humanized transgenic disease models (e.g., APP/PS1, Tau P301S, 5xFAD), all human-specific analytes are robustly quantified. We review species compatibility during initial study scoping.
The standard protocol requires only 15 μL of neat sample volume per well (which is diluted 1:4 on-board to a 60 μL working volume). We recommend providing 30–50 μL total volume to support dead volume, duplicate confirmation, and analytical reserve.
Neurology 4-Plex A/B measures NfL, GFAP, UCH-L1, and Total Tau, making it the premier choice for traumatic brain injury (TBI), stroke, and general neuroaxonal damage. Neurology 4-Plex E measures Aβ40, Aβ42, GFAP, and NfL, making it specifically tailored for Alzheimer's disease and amyloid cascade modeling.
Multiplex and singleplex Simoa assays show near-perfect linear correlation (r > 0.96). However, due to subtle differences in bead surface chemistry and multiplex reagent formulations, a slight proportional numerical offset (typically 5–15 %) can occur. We provide bridging validation protocols to mathematically harmonize multiplex and singleplex datasets across multi-year studies.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×